|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bukhari SNA: Emerging nanotherapeutic
approaches to overcome drug resistance in cancers with update on
clinical trials. Pharmaceutics. 14:8662022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mattiuzzi C and Lippi G: Current cancer
epidemiology. J Epidemiol Glob Health. 9:217–222. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tufail M, Hu JJ, Liang J, He CY, Wan WD,
Huang YQ, Jiang CH, Wu H and Li N: Hallmarks of cancer resistance.
iScience. 27:1099792024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kubik J, Humeniuk E, Adamczuk G,
Madej-Czerwonka B and Korga-Plewko A: Targeting energy metabolism
in cancer treatment. Int J Mol Sci. 23:55722022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pavlova NN, Zhu J and Thompson CB: The
hallmarks of cancer metabolism: Still emerging. Cell Metab.
34:355–377. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Warburg O, Wind F and Negelein E: The
metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Paul S, Ghosh S and Kumar S: Tumor
glycolysis, an essential sweet tooth of tumor cells. Semin Cancer
Biol. 86:1216–1230. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoo HC, Yu YC, Sung Y and Han JM:
Glutamine reliance in cell metabolism. Exp Mol Med. 52:1496–1516.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stine ZE, Schug ZT, Salvino JM and Dang
CV: Targeting cancer metabolism in the era of precision oncology.
Nat Rev Drug Discov. 21:141–162. 2022. View Article : Google Scholar
|
|
13
|
Landau BR, Laszlo J, Stengle J and Burk D:
Certain metabolic and pharmacologic effects in cancer patients
given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst.
21:485–494. 1958.PubMed/NCBI
|
|
14
|
Slack FJ and Chinnaiyan AM: The role of
non-coding RNAs in oncology. Cell. 179:1033–1055. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nemeth K, Bayraktar R, Ferracin M and
Calin GA: Non-coding RNAs in disease: From mechanisms to
therapeutics. Nat Rev Genet. 25:211–232. 2024. View Article : Google Scholar
|
|
16
|
Sanchez-Mejias A and Tay Y: Competing
endogenous RNA networks: Tying the essential knots for cancer
biology and therapeutics. J Hematol Oncol. 8:302015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin W, Zhou Q, Wang CQ, Zhu L, Bi C, Zhang
S, Wang X and Jin H: LncRNAs regulate metabolism in cancer. Int J
Biol Sci. 16:1194–1206. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shih JW, Wang LY, Hung CL, Kung HJ and
Hsieh CL: Non-coding RNAs in castration-resistant prostate cancer:
Regulation of androgen receptor signaling and cancer metabolism.
Int J Mol Sci. 16:28943–28978. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu S, Wang L, Zhao Y, Mo T, Wang B, Lin J
and Yang H: Metabolism-regulating non-coding RNAs in breast cancer:
Roles, mechanisms and clinical applications. J Biomed Sci.
31:252024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keyvani-Ghamsari S, Khorsandi K, Rasul A
and Zaman MK: Current understanding of epigenetics mechanism as a
novel target in reducing cancer stem cells resistance. Clin
Epigenetics. 13:1202021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng Z, Fu M, Hu Y, Wei Y, Wei X and Luo
M: Regulation and signaling pathways in cancer stem cells:
Implications for targeted therapy for cancer. Mol Cancer.
22:1722023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan Y, Li H, Pu W, Chen L, Guo D, Jiang
H, He B, Qin S, Wang K, Li N, et al: Cancer metabolism and tumor
microenvironment: Fostering each other? Sci China Life Sci.
65:236–279. 2022. View Article : Google Scholar
|
|
23
|
Lin X, Wu Z, Hu H, Luo ML and Song E:
Non-coding RNAs rewire cancer metabolism networks. Semin Cancer
Biol. 75:116–126. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang D, Guo Q, You K, Zhang Y, Zheng Y
and Wei T: m6A-modified circARHGAP12 promotes the
aerobic glycolysis of doxorubicin-resistance osteosarcoma by
targeting c-Myc. J Orthop Surg Res. 19:332024. View Article : Google Scholar
|
|
25
|
Zhang Q, Wu J, Zhang X, Cao L, Wu Y and
Miao X: Transcription factor ELK1 accelerates aerobic glycolysis to
enhance osteosarcoma chemoresistance through miR-134/PTBP1
signaling cascade. Aging (Albany NY). 13:6804–6819. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He W, Liang B, Wang C, Li S, Zhao Y, Huang
Q, Liu Z, Yao Z, Wu Q, Liao W, et al: MSC-regulated lncRNA
MACC1-AS1 promotes stemness and chemoresistance through fatty acid
oxidation in gastric cancer. Oncogene. 38:4637–4654. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ge X, Pan MH, Wang L, Li W, Jiang C, He J,
Abouzid K, Liu LZ, Shi Z and Jiang BH: Hypoxia-mediated
mitochondria apoptosis inhibition induces temozolomide treatment
resistance through miR-26a/Bad/Bax axis. Cell Death Dis.
9:11282018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding C, Yi X, Chen X, Wu Z, You H, Chen X,
Zhang G, Sun Y, Bu X, Wu X, et al: Warburg effect-promoted exosomal
circ_0072083 releasing up-regulates NANGO expression through
multiple pathways and enhances temozolomide resistance in glioma. J
Exp Clin Cancer Res. 40:1642021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun X, Sun G, Huang Y, Hao Y, Tang X,
Zhang N, Zhao L, Zhong R and Peng Y: 3-Bromopyruvate regulates the
status of glycolysis and BCNU sensitivity in human hepatocellular
carcinoma cells. Biochem Pharmacol. 177:1139882020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z,
Li W, Hu J, Lu C and Liu Y: PI3K/AKT pathway as a key link
modulates the multidrug resistance of cancers. Cell Death Dis.
11:7972020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Castellví A, Pequerul R, Barracco V,
Juanhuix J, Parés X and Farrés J: Structural and biochemical
evidence that ATP inhibits the cancer biomarker human aldehyde
dehydrogenase 1A3. Commun Biol. 5:3542022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hou GX, Liu PP, Zhang S, Yang M, Liao J,
Yang J, Hu Y, Jiang WQ, Wen S and Huang P: Elimination of stem-like
cancer cell side-population by auranofin through modulation of ROS
and glycolysis. Cell Death Dis. 9:892018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Giddings EL, Champagne DP, Wu MH, Laffin
JM, Thornton TM, Valenca-Pereira F, Culp-Hill R, Fortner KA, Romero
N, East J, et al: Mitochondrial ATP fuels ABC transporter-mediated
drug efflux in cancer chemoresistance. Nat Commun. 12:28042021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu S, Tian H, Li L, Li B, Yang M, Zhou L,
Jiang H, Li Q, Wang W, Nice EC, et al: Nanoengineering a zeolitic
imidazolate framework-8 capable of manipulating energy metabolism
against cancer chemo-phototherapy resistance. Small.
18:e22049262022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roberts DJ and Miyamoto S: Hexokinase II
integrates energy metabolism and cellular protection: Akting on
mitochondria and TORCing to autophagy. Cell Death Differ.
22:248–257. 2015. View Article : Google Scholar :
|
|
36
|
Zhang Z, Deng X, Liu Y, Liu Y, Sun L and
Chen F: PKM2, function and expression and regulation. Cell Biosci.
9:522019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jang M, Kang HJ, Lee SY, Chung SJ, Kang S,
Chi SW, Cho S, Lee SC, Lee CK, Park BC, et al:
Glyceraldehyde-3-phosphate, a glycolytic intermediate, plays a key
role in controlling cell fate via inhibition of caspase activity.
Mol Cells. 28:559–563. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong Q, Niu W, Mu M, Ye C, Wu P, Hu S and
Niu C: Lycorine hydrochloride interferes with energy metabolism to
inhibit chemoresistant glioblastoma multiforme cell growth through
suppressing PDK3. Mol Cell Biochem. 480:355–369. 2025. View Article : Google Scholar
|
|
39
|
Yalcin A, Clem BF, Imbert-Fernandez Y,
Ozcan SC, Peker S, O'Neal J, Klarer AC, Clem AL, Telang S and
Chesney J: 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle
progression and suppresses apoptosis via Cdk1-mediated
phosphorylation of p27. Cell Death Dis. 5:e13372014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shi L, Pan H, Liu Z, Xie J and Han W:
Roles of PFKFB3 in cancer. Signal Transduct Target Ther.
2:170442017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cantelmo AR, Conradi LC, Brajic A, Goveia
J, Kalucka J, Pircher A, Chaturvedi P, Hol J, Thienpont B, Teuwen
LA, et al: Inhibition of the glycolytic activator PFKFB3 in
endothelium induces tumor vessel normalization, impairs metastasis,
and improves chemotherapy. Cancer Cell. 30:968–985. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Morais-Santos F, Granja S,
Miranda-Gonçalves V, Moreira AH, Queirós S, Vilaça JL, Schmitt FC,
Longatto-Filho A, Paredes J, Baltazar F and Pinheiro C: Targeting
lactate transport suppresses in vivo breast tumour growth.
Oncotarget. 6:19177–19189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hraběta J, Belhajová M, Šubrtová H, Merlos
Rodrigo MA, Heger Z and Eckschlager T: Drug sequestration in
lysosomes as one of the mechanisms of chemoresistance of cancer
cells and the possibilities of its inhibition. Int J Mol Sci.
21:43922020. View Article : Google Scholar
|
|
44
|
Bogdanov A, Bogdanov A, Chubenko V, Volkov
N, Moiseenko F and Moiseyenko V: Tumor acidity: From hallmark of
cancer to target of treatment. Front Oncol. 12:9791542022.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mahoney BP, Raghunand N, Baggett B and
Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. I.
Acid pH affects the distribution of chemotherapeutic agents in
vitro. Biochem Pharmacol. 66:1207–1218. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alfarouk KO, Stock CM, Taylor S, Walsh M,
Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO,
Harguindey S, et al: Resistance to cancer chemotherapy: Failure in
drug response from ADME to P-gp. Cancer Cell Int. 15:712015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dong Q, Zhou C, Ren H, Zhang Z, Cheng F,
Xiong Z, Chen C, Yang J, Gao J, Zhang Y, et al: Lactate-induced
MRP1 expression contributes to metabolism-based etoposide
resistance in non-small cell lung cancer cells. Cell Commun Signal.
18:1672020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li J, Gao N, Gao Z, Liu W, Pang B, Dong X,
Li Y and Fan T: The emerging role of exosomes in cancer
chemoresistance. Front Cell Dev Biol. 9:7379622021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brown TP and Ganapathy V: Lactate/GPR81
signaling and proton motive force in cancer: Role in angiogenesis,
immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther.
206:1074512020. View Article : Google Scholar
|
|
50
|
Sandforth L, Ammar N, Dinges LA, Röcken C,
Arlt A, Sebens S and Schäfer H: Impact of the monocarboxylate
transporter-1 (MCT1)-mediated cellular import of lactate on
stemness properties of human pancreatic adenocarcinoma cells †.
Cancers (Basel). 12:5812020. View Article : Google Scholar
|
|
51
|
Takada T, Takata K and Ashihara E:
Inhibition of monocarboxylate transporter 1 suppresses the
proliferation of glioblastoma stem cells. J Physiol Sci.
66:387–396. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang XY, Zhang M, Cong Q, Zhang MX, Zhang
MY, Lu YY and Xu CJ: Hexokinase 2 confers resistance to cisplatin
in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Int J Biochem Cell Biol. 95:9–16. 2018. View Article : Google Scholar
|
|
53
|
Thirusangu P, Ray U, Sarkar Bhattacharya
S, Oien DB, Jin L, Staub J, Kannan N, Molina JR and Shridhar V:
PFKFB3 regulates cancer stemness through the hippo pathway in small
cell lung carcinoma. Oncogene. 41:4003–4017. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Amin S, Yang P and Li Z: Pyruvate kinase
M2: A multifarious enzyme in non-canonical localization to promote
cancer progression. Biochim Biophys Acta Rev Cancer. 1871:331–341.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lee SH, Golinska M and Griffiths JR:
HIF-1-independent mechanisms regulating metabolic adaptation in
hypoxic cancer cells. Cells. 10:23712021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tirpe AA, Gulei D, Ciortea SM, Crivii C
and Berindan-Neagoe I: Hypoxia: Overview on hypoxia-mediated
mechanisms with a focus on the role of HIF genes. Int J Mol Sci.
20:61402019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nagao A, Kobayashi M, Koyasu S, Chow CCT
and Harada H: HIF-1-dependent reprogramming of glucose metabolic
pathway of cancer cells and its therapeutic significance. Int J Mol
Sci. 20:2382019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Delgado JM and Shoemaker CJ: An unexpected
journey for BNIP3. Autophagy. 20:1447–1448. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Geng Y, Zheng X, Zhang D, Wei S, Feng J,
Wang W, Zhang L, Wu C and Hu W: CircHIF1A induces cetuximab
resistance in colorectal cancer by promoting HIF1α-mediated
glycometabolism alteration. Biol Direct. 19:362024. View Article : Google Scholar
|
|
60
|
Xu G, Li M, Wu J, Qin C, Tao Y and He H:
Circular RNA circ-NRIP1 sponges microRNA-138-5p to maintain
hypoxia-induced resistance to 5-fluorouracil through
HIF-1α-dependent glucose metabolism in gastric carcinoma. Cancer
Manag Res. 12:2789–2802. 2020. View Article : Google Scholar :
|
|
61
|
Li Q, Sun H, Luo D, Gan L, Mo S, Dai W,
Liang L, Yang Y, Xu M, Li J, et al: Lnc-RP11-536 K7.3/SOX2/HIF-1α
signaling axis regulates oxaliplatin resistance in patient-derived
colorectal cancer organoids. J Exp Clin Cancer Res. 40:3482021.
View Article : Google Scholar
|
|
62
|
Chen F, Chen J, Yang L, Liu J, Zhang X,
Zhang Y, Tu Q, Yin D, Lin D, Wong PP, et al: Extracellular
vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated
macrophages regulates aerobic glycolysis of breast cancer cells.
Nat Cell Biol. 21:498–510. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Xu F, Huang M, Chen Q, Niu Y, Hu Y, Hu P,
Chen D, He C, Huang K, Zeng Z, et al: LncRNA HIF1A-AS1 promotes
gemcitabine resistance of pancreatic cancer by enhancing glycolysis
through modulating the AKT/YB1/HIF1α pathway. Cancer Res.
81:5678–5691. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zeng Z, Zhao Y, Chen Q, Zhu S, Niu Y, Ye
Z, Hu P, Chen D, Xu P, Chen J, et al: Hypoxic exosomal
HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic
pancreatic cancer cells via enhancing glycolysis. Oncogene.
40:5505–5517. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Meng Y, Xu X, Luan H, Li L, Dai W, Li Z
and Bian J: The progress and development of GLUT1 inhibitors
targeting cancer energy metabolism. Future Med Chem. 11:2333–2352.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Dong P, Wang F, Taheri M, Xiong Y, Ihira
K, Kobayashi N, Konno Y, Yue J and Watari H: Long non-coding RNA
TMPO-AS1 promotes GLUT1-mediated glycolysis and paclitaxel
resistance in endometrial cancer cells by interacting with miR-140
and miR-143. Front Oncol. 12:9129352022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ma J, Qi G and Li L: A novel serum
exosomes-based biomarker hsa_circ_0002130 facilitates
osimertinib-resistance in non-small cell lung cancer by sponging
miR-498. Onco Targets Ther. 13:5293–5307. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li P, Yang X, Cheng Y, Zhang X, Yang C,
Deng X, Li P, Tao J, Yang H, Wei J, et al: MicroRNA-218 increases
the sensitivity of bladder cancer to cisplatin by targeting Glut1.
Cell Physiol Biochem. 41:921–932. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Tu MJ, Duan Z, Liu Z, Zhang C, Bold RJ,
Gonzalez FJ, Kim EJ and Yu AM: MicroRNA-1291-5p sensitizes
pancreatic carcinoma cells to arginine deprivation and chemotherapy
through the regulation of arginolysis and glycolysis. Mol
Pharmacol. 98:686–694. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zuo J, Tang J, Lu M, Zhou Z, Li Y, Tian H,
Liu E, Gao B, Liu T and Shao P: Glycolysis rate-limiting enzymes:
Novel potential regulators of rheumatoid arthritis pathogenesis.
Front Immunol. 12:7797872021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Xu J, Xu Y, Ye G and Qiu J: LncRNA-SNHG1
promotes paclitaxel resistance of gastric cancer cells through
modulating the miR-216b-5p-hexokianse 2 axis. J Chemother.
35:527–538. 2023. View Article : Google Scholar
|
|
72
|
Shi H, Li K, Feng J, Liu G, Feng Y and
Zhang X: LncRNA-DANCR interferes with miR-125b-5p/HK2 axis to
desensitize colon cancer cells to cisplatin vis activating
anaerobic glycolysis. Front Oncol. 10:10342020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhang H, Zhao L, Ren P and Sun X: LncRNA
MBNL1-AS1 knockdown increases the sensitivity of hepatocellular
carcinoma to tripterine by regulating miR-708-5p-mediated
glycolysis. Biotechnol Genet Eng Rev. 40:1407–1424. 2024.
View Article : Google Scholar
|
|
74
|
Deng Y, Li X, Feng J and Zhang X:
Overexpression of miR-202 resensitizes imatinib resistant chronic
myeloid leukemia cells through targetting Hexokinase 2. Biosci Rep.
38:BSR201713832018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Jiang JX, Gao S, Pan YZ, Yu C and Sun CY:
Overexpression of microRNA-125b sensitizes human hepatocellular
carcinoma cells to 5-fluorouracil through inhibition of glycolysis
by targeting hexokinase II. Mol Med Rep. 10:995–1002. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang Y, Liu Y and Xu X: Knockdown of
LncRNA-UCA1 suppresses chemoresistance of pediatric AML by
inhibiting glycolysis through the microRNA-125a/hexokinase 2
pathway. J Cell Biochem. 119:6296–6308. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Shi H, Li K, Feng J and Zhang X:
Overexpression of long non-coding RNA urothelial carcinoma
associated 1 causes paclitaxel (Taxol) resistance in colorectal
cancer cells by promoting glycolysis. J Chemother. 33:409–419.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Deng X, Li D, Ke X, Wang Q, Yan S, Xue Y,
Wang Q and Zheng H: Mir-488 alleviates chemoresistance and
glycolysis of colorectal cancer by targeting PFKFB3. J Clin Lab
Anal. 35:e235782021. View Article : Google Scholar
|
|
79
|
Gao Y, Liu C, Xu X, Wang Y and Jiang Y:
Circular RNA sterile alpha motif domain containing 4A contributes
to cell 5-fluorouracil resistance in colorectal cancer by
regulating the
miR-545-3p/6-phosphofructo-2-kinase/fructose-2,6-bisphosphataseisotype
3 axis. Anticancer Drugs. 33:553–563. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yang W and Lu Z: Pyruvate kinase M2 at a
glance. J Cell Sci. 128:1655–1660. 2015.PubMed/NCBI
|
|
81
|
Dayton TL, Jacks T and Vander Heiden MG:
PKM2, cancer metabolism, and the road ahead. EMBO Rep.
17:1721–1730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Yu Y, Liang Y, Xie F, Zhang Z, Zhang P,
Zhao X, Zhang Z, Liang Z, Li D, Wang L, et al: Tumor-associated
macrophage enhances PD-L1-mediated immune escape of bladder cancer
through PKM2 dimer-STAT3 complex nuclear translocation. Cancer
Lett. 593:2169642024. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yao Y, Chen X, Wang X, Li H, Zhu Y, Li X,
Xiao Z, Zi T, Qin X, Zhao Y, et al: Glycolysis related lncRNA
SNHG3/miR-139-5p/PKM2 axis promotes castration-resistant prostate
cancer (CRPC) development and enzalutamide resistance. Int J Biol
Macromol. 260:1296352024. View Article : Google Scholar
|
|
84
|
Zhong W, Wang C and Sun Y: LncRNA PCIF1
promotes aerobic glycolysis in A549/DDP cells by competitively
binding miR-326 to regulate PKM expression. Mol Cell Probes.
77:1019772024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wu H, Du J, Li C, Li H, Guo H and Li Z:
Kaempferol can reverse the 5-Fu resistance of colorectal cancer
cells by inhibiting PKM2-mediated glycolysis. Int J Mol Sci.
23:35442022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Bian Z, Yang F, Xu P, Gao G, Yang C, Cao
Y, Yao S, Wang X, Yin Y, Fei B and Huang Z: LINC01852 inhibits the
tumorigenesis and chemoresistance in colorectal cancer by
suppressing SRSF5-mediated alternative splicing of PKM. Mol Cancer.
23:232024. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhu Z, Tang G and Yan J: MicroRNA-122
regulates docetaxel resistance of prostate cancer cells by
regulating PKM2. Exp Ther Med. 20:2472020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Pan C, Wang X, Shi K, Zheng Y, Li J, Chen
Y, Jin L and Pan Z: MiR-122 reverses the doxorubicin-resistance in
hepatocellular carcinoma cells through regulating the tumor
metabolism. PLoS One. 11:e01520902016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wang X, Zhang H, Yang H, Bai M, Ning T,
Deng T, Liu R, Fan Q, Zhu K, Li J, et al: Exosome-delivered circRNA
promotes glycolysis to induce chemoresistance through the
miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 14:539–555.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen
X and Peng C: Pyruvate kinase M2 (PKM2) in cancer and cancer
therapeutics. Cancer Lett. 503:240–248. 2021. View Article : Google Scholar
|
|
91
|
Zhang M, Zhang H, Hong H and Zhang Z:
MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib
therapy by antagonizing PKM2-mediated glycolysis pathway. Am J
Cancer Res. 9:765–778. 2019.PubMed/NCBI
|
|
92
|
Jiang CF, Xie YX, Qian YC, Wang M, Liu LZ,
Shu YQ, Bai XM and Jiang BH: TBX15/miR-152/KIF2C pathway regulates
breast cancer doxorubicin resistance via promoting PKM2
ubiquitination. Cancer Cell Int. 21:5422021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Li X, Zhang Y and Wang X, Lin F, Cheng X,
Wang Z and Wang X: Long non-coding RNA CTSLP8 mediates ovarian
cancer progression and chemotherapy resistance by modulating
cellular glycolysis and regulating c-Myc expression through PKM2.
Cell Biol Toxicol. 38:1027–1045. 2022. View Article : Google Scholar :
|
|
94
|
Van Wilpe S, Koornstra R, Den Brok M, De
Groot JW, Blank C, De Vries J, Gerritsen W and Mehra N: Lactate
dehydrogenase: A marker of diminished antitumor immunity.
Oncoimmunology. 9:17319422020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Pei LJ, Sun PJ, Ma K, Guo YY, Wang LY and
Liu FD: LncRNA-SNHG7 interferes with miR-34a to de-sensitize
gastric cancer cells to cisplatin. Cancer Biomark. 30:127–137.
2021. View Article : Google Scholar
|
|
96
|
Hua G, Zeng ZL, Shi YT, Chen W, He LF and
Zhao GF: LncRNA XIST contributes to cisplatin resistance of lung
cancer cells by promoting cellular glycolysis through sponging
miR-101-3p. Pharmacology. 106:498–508. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Li G, Li Y and Wang DY: Overexpression of
miR-329-3p sensitizes osteosarcoma cells to cisplatin through
suppression of glucose metabolism by targeting LDHA. Cell Biol Int.
45:766–774. 2021. View Article : Google Scholar
|
|
98
|
Hu J, Huang L, Ding Q, Lv J and Chen Z:
Long noncoding RNA HAGLR sponges miR-338-3p to promote 5-Fu
resistance in gastric cancer through targeting the LDHA-glycolysis
pathway. Cell Biol Int. 46:173–184. 2022. View Article : Google Scholar
|
|
99
|
Shao X, Zheng X, Ma D, Liu Y and Liu G:
Inhibition of lncRNA-NEAT1 sensitizes 5-Fu resistant cervical
cancer cells through de-repressing the microRNA-34a/LDHA axis.
Biosci Rep. 41:BSR202005332021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Shi L, Duan R, Sun Z, Jia Q, Wu W, Wang F,
Liu J, Zhang H and Xue X: LncRNA GLTC targets LDHA for
succinylation and enzymatic activity to promote progression and
radioiodine resistance in papillary thyroid cancer. Cell Death
Differ. 30:1517–1532. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Purhonen J, Klefström J and Kallijärvi J:
MYC-an emerging player in mitochondrial diseases. Front Cell Dev
Biol. 11:12576512023. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Wang H, Wang L, Pan H, Wang Y, Shi M, Yu
H, Wang C, Pan X and Chen Z: Exosomes derived from macrophages
enhance aerobic glycolysis and chemoresistance in lung cancer by
stabilizing c-Myc via the inhibition of NEDD4L. Front Cell Dev
Biol. 8:6206032021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Jiang X, Guo S, Wang S, Zhang Y, Chen H,
Wang Y, Liu R, Niu Y and Xu Y: EIF4A3-induced circARHGAP29 promotes
aerobic glycolysis in docetaxel-resistant prostate cancer through
IGF2BP2/c-Myc/LDHA signaling. Cancer Res. 82:831–845. 2022.
View Article : Google Scholar
|
|
104
|
Anwar S, Shamsi A, Mohammad T, Islam A and
Hassan MI: Targeting pyruvate dehydrogenase kinase signaling in the
development of effective cancer therapy. Biochim Biophys Acta Rev
Cancer. 1876:1885682021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zhuang L, Zhang B, Liu X, Lin L, Wang L,
Hong Z and Chen J: Exosomal miR-21-5p derived from
cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis
and inhibits chemosensitivity of its progenitor SKOV3 cells by
targeting PDHA1. Cell Biol Int. 45:2140–2149. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Kim JW, Tchernyshyov I, Semenza GL and
Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase
kinase: A metabolic switch required for cellular adaptation to
hypoxia. Cell Metab. 3:177–185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Qian Y, Wu X, Wang H, Hou G, Han X and
Song W: MicroRNA-4290 suppresses PDK1-mediated glycolysis to
enhance the sensitivity of gastric cancer cell to cisplatin. Braz J
Med Biol Res. 53:e93302020. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Xie Y, Shi Z, Qian Y, Jiang C, Liu W, Liu
B and Jiang B: HDAC2- and EZH2-mediated histone modifications
induce PDK1 expression through miR-148a downregulation in breast
cancer progression and adriamycin resistance. Cancers (Basel).
14:36002022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ding Y, Gao S, Zheng J and Chen X:
Blocking lncRNA-SNHG16 sensitizes gastric cancer cells to 5-Fu
through targeting the miR-506-3p-PTBP1-mediated glucose metabolism.
Cancer Metab. 10:202022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Chen X, Luo R, Zhang Y, Ye S, Zeng X, Liu
J, Huang D, Liu Y, Liu Q, Luo ML and Song E: Long noncoding RNA
DIO3OS induces glycolytic-dominant metabolic reprogramming to
promote aromatase inhibitor resistance in breast cancer. Nat
Commun. 13:71602022. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yang GJ, Tao F, Zhong HJ, Yang C and Chen
J: Targeting PGAM1 in cancer: An emerging therapeutic opportunity.
Eur J Med Chem. 244:1147982022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Liu Z, Zheng N, Li J, Li C, Zheng D, Jiang
X, Ge X, Liu M, Liu L, Song Z, et al: N6-methyladenosine-modified
circular RNA QSOX1 promotes colorectal cancer resistance to
anti-CTLA-4 therapy through induction of intratumoral regulatory T
cells. Drug Resist Updat. 65:1008862022. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Poliaková M, Aebersold DM, Zimmer Y and
Medová M: The relevance of tyrosine kinase inhibitors for global
metabolic pathways in cancer. Mol Cancer. 17:272018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Li C, Liu FY, Shen Y, Tian Y and Han FJ:
Research progress on the mechanism of glycolysis in ovarian cancer.
Front Immunol. 14:12848532023. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Fontana F, Giannitti G, Marchesi S and
Limonta P: The PI3K/Akt pathway and glucose metabolism: A dangerous
liaison in cancer. Int J Biol Sci. 20:3113–3125. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Wang L, Jiang P, Li J, Huang Y, Wen J, Wu
Z, Chen Y and Hu J: Loss of MiR-155 sensitizes
FLT3-ITD+AML to chemotherapy and FLT3 inhibitors via
glycolysis blocking by targeting PIK3R1. J Cancer. 14:99–113. 2023.
View Article : Google Scholar :
|
|
117
|
Chen X, Song Y, Tian Y, Dong X, Chang Y
and Wang W: miR-149-3p enhances drug sensitivity of AML cells by
inhibiting warburg effect through PI3K/AKT pathway. Cell Biochem
Biophys. 82:3287–3296. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Lim SO, Li CW, Xia W, Lee HH, Chang SS,
Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, et al: EGFR signaling
enhances aerobic glycolysis in triple-negative breast cancer cells
to promote tumor growth and immune escape. Cancer Res.
76:1284–1296. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Concha-Benavente F and Ferris RL:
Reversing EGFR mediated immunoescape by targeted monoclonal
antibody therapy. Front Pharmacol. 8:3322017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Gao SJ, Ren SN, Liu YT, Yan HW and Chen
XB: Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells
through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2
axis. Mol Ther Oncolytics. 23:14–25. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wen JF, Jiang YQ, Li C, Dai XK, Wu T and
Yin WZ: LncRNA-SARCC sensitizes osteosarcoma to cisplatin through
the miR-143-mediated glycolysis inhibition by targeting Hexokinase
2. Cancer Biomark. 28:231–246. 2020. View Article : Google Scholar
|
|
122
|
Chen W, Chen Y and Hui T: microRNA-143
interferes the EGFR-stimulated glucose metabolism to re-sensitize
5-FU resistant colon cancer cells via targeting hexokinase 2. J
Chemother. 35:539–549. 2023. View Article : Google Scholar
|
|
123
|
Cheng WL, Feng PH, Lee KY, Chen KY, Sun
WL, Van Hiep N, Luo CS and Wu SM: The role of EREG/EGFR pathway in
tumor progression. Int J Mol Sci. 22:128282021. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
He M, Jin Q, Chen C, Liu Y, Ye X, Jiang Y,
Ji F, Qian H, Gan D, Yue S, et al: The miR-186-3p/EREG axis
orchestrates tamoxifen resistance and aerobic glycolysis in breast
cancer cells. Oncogene. 38:5551–5565. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Asl ER, Amini M, Najafi S, Mansoori B,
Mokhtarzadeh A, Mohammadi A, Lotfinejad P, Bagheri M, Shirjang S,
Lotfi Z, et al: Interplay between MAPK/ERK signaling pathway and
MicroRNAs: A crucial mechanism regulating cancer cell metabolism
and tumor progression. Life Sci. 278:1194992021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
He Z, Zhong Y, Lv T, Wang J, Jin Y, Li F
and Hu H: PP4R1 promotes glycolysis and gallbladder cancer
progression through facilitating ERK1/2 mediated PKM2 nuclear
translocation. Cancer Lett. 586:2166772024. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Li X, Tsauo J, Geng C, Zhao H, Lei X and
Li X: Ginsenoside Rg3 Decreases NHE1 expression via inhibiting
EGF-EGFR-ERK1/2-HIF-1 α pathway in hepatocellular carcinoma: A
novel antitumor mechanism. Am J Chin Med. 46:1915–1931. 2018.
View Article : Google Scholar
|
|
128
|
Li M, Cai O, Yu Y and Tan S: Paeonol
inhibits the malignancy of Apatinib-resistant gastric cancer cells
via LINC00665/miR-665/MAPK1 axis. Phytomedicine. 96:1539032022.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Garcia D and Shaw RJ: AMPK: Mechanisms of
cellular energy sensing and restoration of metabolic balance. Mol
Cell. 66:789–800. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Li YZ, Deng J, Zhang XD, Li DY, Su LX, Li
S, Pan JM, Lu L, Ya JQ, Yang N, et al: Naringenin enhances the
efficacy of ferroptosis inducers by attenuating aerobic glycolysis
by activating the AMPK-PGC1α signalling axis in liver cancer.
Heliyon. 10:e322882024. View Article : Google Scholar
|
|
131
|
Lyu X, Wang J, Guo X, Wu G, Jiao Y, Faleti
OD, Liu P, Liu T, Long Y, Chong T, et al: EBV-miR-BART1-5P
activates AMPK/mTOR/HIF1 pathway via a PTEN independent manner to
promote glycolysis and angiogenesis in nasopharyngeal carcinoma.
PLoS Pathog. 14:e10074842018. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Barisciano G, Colangelo T, Rosato V,
Muccillo L, Taddei ML, Ippolito L, Chiarugi P, Galgani M,
Bruzzaniti S, Matarese G, et al: miR-27a is a master regulator of
metabolic reprogramming and chemoresistance in colorectal cancer.
Br J Cancer. 122:1354–1366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Vallée A, Lecarpentier Y and Vallée JN:
The key role of the WNT/β-catenin pathway in metabolic
reprogramming in cancers under normoxic conditions. Cancers
(Basel). 13:55572021. View Article : Google Scholar
|
|
134
|
Chen L, Hu N, Wang C and Zhao H: HOTAIRM1
knockdown enhances cytarabine-induced cytotoxicity by suppression
of glycolysis through the Wnt/β-catenin/PFKP pathway in acute
myeloid leukemia cells. Arch Biochem Biophys. 680:1082442020.
View Article : Google Scholar
|
|
135
|
Zhang Z, Tan X, Luo J, Yao H, Si Z and
Tong JS: The miR-30a-5p/CLCF1 axis regulates sorafenib resistance
and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis.
11:9022020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Yi Q, Wei J and Li Y: Effects of
miR-103a-3p targeted regulation of TRIM66 axis on docetaxel
resistance and glycolysis in prostate cancer cells. Front Genet.
12:8137932022. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Wang Z, Wang Y, Li Z, Xue W, Hu S and Kong
X: Lipid metabolism as a target for cancer drug resistance:
Progress and prospects. Front Pharmacol. 14:12743352023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Qin J, Ye L, Wen X, Zhang X, Di Y, Chen Z
and Wang Z: Fatty acids in cancer chemoresistance. Cancer Lett.
572:2163522023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Ladanyi A, Mukherjee A, Kenny HA, Johnson
A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag
A, et al: Adipocyte-induced CD36 expression drives ovarian cancer
progression and metastasis. Oncogene. 37:2285–2301. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Guo Y, Yang L, Guo W, Wei L and Zhou Y:
FV-429 enhances the efficacy of paclitaxel in NSCLC by
reprogramming HIF-1α-modulated FattyAcid metabolism. Chem Biol
Interact. 350:1097022021. View Article : Google Scholar
|
|
141
|
Ventura R, Mordec K, Waszczuk J, Wang Z,
Lai J, Fridlib M, Buckley D, Kemble G and Heuer TS: Inhibition of
de novo palmitate synthesis by fatty acid synthase induces
apoptosis in tumor cells by remodeling cell membranes, inhibiting
signaling pathways, and reprogramming gene expression.
EBioMedicine. 2:808–824. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Liu S, Sun Y, Hou Y, Yang L, Wan X, Qin Y,
Liu Y, Wang R, Zhu P, Teng Y and Liu M: A novel lncRNA
ROPM-mediated lipid metabolism governs breast cancer stem cell
properties. J Hematol Oncol. 14:1782021. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Varghese E, Samuel SM, Líšková A, Samec M,
Kubatka P and Büsselberg D: Targeting glucose metabolism to
overcome resistance to anticancer chemotherapy in breast cancer.
Cancers (Basel). 12:22522020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Eytan GD, Regev R, Oren G and Assaraf YG:
The role of passive transbilayer drug movement in multidrug
resistance and its modulation. J Biol Chem. 271:12897–12902. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Wang X, He S, Gu Y, Wang Q, Chu X, Jin M,
Xu L, Wu Q, Zhou Q, Wang B, et al: Fatty acid receptor GPR120
promotes breast cancer chemoresistance by upregulating ABC
transporters expression and fatty acid synthesis. EBioMedicine.
40:251–262. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Kuan CY, Walker TH, Luo PG and Chen CF:
Long-chain polyunsaturated fatty acids promote paclitaxel
cytotoxicity via inhibition of the MDR1 gene in the human colon
cancer Caco-2 cell line. J Am Coll Nutr. 30:265–273. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Royo-García A, Courtois S, Parejo-Alonso
B, Espiau-Romera P and Sancho P: Lipid droplets as metabolic
determinants for stemness and chemoresistance in cancer. World J
Stem Cells. 13:1307–1317. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Huang KB, Pan YH, Shu GN, Yao HH, Liu X,
Zhou M, Wei JH, Chen ZH, Lu J, Feng ZH, et al: Circular RNA
circSNX6 promotes sunitinib resistance in renal cell carcinoma
through the miR-1184/GPCPD1/lysophosphatidic acid axis. Cancer
Lett. 523:121–134. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zhang X, Xu Y, Ma L, Yu K, Niu Y, Xu X,
Shi Y, Guo S, Xue X, Wang Y, et al: Essential roles of exosome and
circRNA_101093 on ferroptosis desensitization in lung
adenocarcinoma. Cancer Commun (Lond). 42:287–313. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Nan Y, Luo Q, Wu X, Liu S, Zhao P, Chang
W, Zhou A and Liu Z: DLGAP1-AS2-mediated phosphatidic acid
synthesis activates YAP signaling and confers chemoresistance in
squamous cell carcinoma. Cancer Res. 82:2887–2903. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Huang X, Taeb S, Jahangiri S, Emmenegger
U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, et al:
miRNA-95 mediates radioresistance in tumors by targeting the
sphingolipid phosphatase SGPP1. Cancer Res. 73:6972–6986. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Kopecka J, Trouillas P, Gašparović AČ,
Gazzano E, Assaraf YG and Riganti C: Phospholipids and cholesterol:
Inducers of cancer multidrug resistance and therapeutic targets.
Drug Resist Updat. 49:1006702020. View Article : Google Scholar
|
|
153
|
Palma GBH and Kaur M: miRNA-128 and
miRNA-223 regulate cholesterol-mediated drug resistance in breast
cancer. IUBMB Life. 75:743–764. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Wolfe AR, Bambhroliya A, Reddy JP, Debeb
BG, Huo L, Larson R, Li L, Ueno NT and Woodward WA: MiR-33a
decreases high-density lipoprotein-induced radiation sensitivity in
breast cancer. Int J Radiat Oncol Biol Phys. 95:791–799. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta
P, Wei L, Ashby CR Jr, Yang DH and Chen ZS: Modulating ROS to
overcome multidrug resistance in cancer. Drug Resist Updat.
41:1–25. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Kennedy L, Sandhu JK, Harper ME and
Cuperlovic-Culf M: Role of glutathione in cancer: From mechanisms
to therapies. Biomolecules. 10:14292020. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Castelli S, De Falco P, Ciccarone F,
Desideri E and Ciriolo MR: Lipid catabolism and ROS in cancer: A
bidirectional liaison. Cancers (Basel). 13:54842021. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Wang Y, Lu JH, Wang F, Wang YN, He MM, Wu
QN, Lu YX, Yu HE, Chen ZH, Zhao Q, et al: Inhibition of fatty acid
catabolism augments the efficacy of oxaliplatin-based chemotherapy
in gastrointestinal cancers. Cancer Lett. 473:74–89. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Farge T, Saland E, de Toni F, Aroua N,
Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, et al:
Chemotherapy-resistant human acute myeloid leukemia cells are not
enriched for leukemic stem cells but require oxidative metabolism.
Cancer Discov. 7:716–735. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
De Oliveira MP and Liesa M: The role of
mitochondrial fat oxidation in cancer cell proliferation and
survival. Cells. 9:26002020. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Luo J, Hong Y, Tao X, Wei X, Zhang L and
Li Q: An indispensable role of CPT-1a to survive cancer cells
during energy stress through rewiring cancer metabolism. Tumour
Biol. 37:15795–15804. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Snaebjornsson MT, Janaki-Raman S and
Schulze A: Greasing the wheels of the cancer machine: The role of
lipid metabolism in cancer. Cell Metab. 31:62–76. 2020. View Article : Google Scholar
|
|
163
|
Chan YT, Wu J, Lu Y, Li Q, Feng Z, Xu L,
Yuan H, Xing T, Zhang C, Tan HY, et al: Loss of lncRNA LINC01056
leads to sorafenib resistance in HCC. Mol Cancer. 23:742024.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Wu H, Liu B, Chen Z, Li G and Zhang Z:
MSC-induced lncRNA HCP5 drove fatty acid oxidation through
miR-3619-5p/AMPK/PGC1α/CEBPB axis to promote stemness and
chemo-resistance of gastric cancer. Cell Death Dis. 11:2332020.
View Article : Google Scholar
|
|
165
|
Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W and
Wang J: Molecular mechanisms of ferroptosis and its role in cancer
therapy. J Cell Mol Med. 23:4900–4912. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Dos Santos AF, Fazeli G, Xavier da Silva
TN and Friedmann Angeli JP: Ferroptosis: Mechanisms and
implications for cancer development and therapy response. Trends
Cell Biol. 33:1062–1076. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Koppula P, Zhuang L and Gan B: Cystine
transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient
dependency, and cancer therapy. Protein Cell. 12:599–620. 2021.
View Article : Google Scholar :
|
|
168
|
Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao
N, Sun B and Wang G: Ferroptosis: Past, present and future. Cell
Death Dis. 11:882020. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Qu S, Qi S, Zhang H, Li Z, Wang K, Zhu T,
Ye R, Zhang W, Huang G and Yi GZ: Albumin-bound paclitaxel augment
temozolomide treatment sensitivity of glioblastoma cells by
disrupting DNA damage repair and promoting ferroptosis. J Exp Clin
Cancer Res. 42:2852023. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Lu Y, Chan YT, Tan HY, Zhang C, Guo W, Xu
Y, Sharma R, Chen ZS, Zheng YC, Wang N and Feng Y: Epigenetic
regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates
sorafenib resistance in human hepatocellular carcinoma. J Exp Clin
Cancer Res. 41:32022. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Pope LE and Dixon SJ: Regulation of
ferroptosis by lipid metabolism. Trends Cell Biol. 33:1077–1087.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Zhong S, Wang Z, Yang J, Jiang D and Wang
K: Ferroptosis-related oxaliplatin resistance in multiple cancers:
Potential roles and therapeutic implications. Heliyon.
10:e376132024. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Zou Y, Zheng S, Xie X, Ye F, Hu X, Tian Z,
Yan SM, Yang L, Kong Y, Tang Y, et al: N6-methyladenosine regulated
FGFR4 attenuates ferroptotic cell death in recalcitrant
HER2-positive breast cancer. Nat Commun. 13:26722022. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Baird L and Dinkova-Kostova AT: The
cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol.
85:241–272. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Sun X, Niu X, Chen R, He W, Chen D, Kang R
and Tang D: Metallothionein-1G facilitates sorafenib resistance
through inhibition of ferroptosis. Hepatology. 64:488–500. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Chen X, Kang R, Kroemer G and Tang D:
Broadening horizons: The role of ferroptosis in cancer. Nat Rev
Clin Oncol. 18:280–296. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Zhang W, Li Q, Zhang Y, Wang Z, Yuan S,
Zhang X, Zhao M, Zhuang W and Li B: Multiple myeloma with high
expression of SLC7A11 is sensitive to erastin-induced ferroptosis.
Apoptosis. 29:412–423. 2024. View Article : Google Scholar
|
|
178
|
Xu X, Zhang X, Wei C, Zheng D, Lu X, Yang
Y, Luo A, Zhang K, Duan X and Wang Y: Targeting SLC7A11
specifically suppresses the progression of colorectal cancer stem
cells via inducing ferroptosis. Eur J Pharm Sci. 152:1054502020.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Zheng Y, Li L, Chen H, Zheng Y, Tan X,
Zhang G, Jiang R, Yu H, Lin S, Wei Y, et al: Luteolin exhibits
synergistic therapeutic efficacy with erastin to induce ferroptosis
in colon cancer cells through the HIC1-mediated inhibition of GPX4
expression. Free Radic Biol Med. 208:530–544. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Yin LB, Li ZW, Wang JL, Wang L, Hou L, Hu
SY, Chen H, Luo P, Cui XB and Zhu JL: Sulfasalazine inhibits
esophageal cancer cell proliferation by mediating ferroptosis. Chem
Biol Drug Des. 102:730–737. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Yang J, Zhou Y, Xie S, Wang J, Li Z, Chen
L, Mao M, Chen C, Huang A, Chen Y, et al: Metformin induces
Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. J
Exp Clin Cancer Res. 40:2062021. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Sui X, Zhang R, Liu S, Duan T, Zhai L,
Zhang M, Han X, Xiang Y, Huang X, Lin H and Xie T: RSL3 drives
ferroptosis through GPX4 inactivation and ROS production in
colorectal cancer. Front Pharmacol. 9:13712018. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Gaschler MM, Andia AA, Liu H, Csuka JM,
Hurlocker B, Vaiana CA, Heindel DW, Zuckerman DS, Bos PH, Reznik E,
et al: FINO2 initiates ferroptosis through GPX4
inactivation and iron oxidation. Nat Chem Biol. 14:507–515. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Cheff DM, Huang C, Scholzen KC, Gencheva
R, Ronzetti MH, Cheng Q, Hall MD and Arnér ESJ: The ferroptosis
inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4
but of TXNRD1. Redox Biol. 62:1027032023. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Wang Y, Yuan X, Ren M and Wang Z:
Ferroptosis: A new research direction of artemisinin and its
derivatives in anti-cancer treatment. Am J Chin Med. 52:161–181.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Chen GQ, Benthani FA, Wu J, Liang D, Bian
ZX and Jiang X: Artemisinin compounds sensitize cancer cells to
ferroptosis by regulating iron homeostasis. Cell Death Differ.
27:242–254. 2020. View Article : Google Scholar :
|
|
187
|
Li J, Li Y, Wang D, Liao R and Wu Z: PLAG1
interacts with GPX4 to conquer vulnerability to sorafenib induced
ferroptosis through a PVT1/miR-195-5p axis-dependent manner in
hepatocellular carcinoma. J Exp Clin Cancer Res. 43:1432024.
View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Nalla LV and Khairnar A: Empagliflozin
drives ferroptosis in anoikis-resistant cells by activating
miR-128-3p dependent pathway and inhibiting CD98hc in breast
cancer. Free Radic Biol Med. 220:288–300. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Li X, Li Y, Lian P, Lv Q and Liu F:
Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by
adsorbing miR-450b-5p to avert sorafenib resistance in
hepatocellular carcinoma. Hum Exp Toxicol. 42:96032712211428182023.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Zhang H, Deng T, Liu R, Ning T, Yang H,
Liu D, Zhang Q, Lin D, Ge S, Bai M, et al: CAF secreted miR-522
suppresses ferroptosis and promotes acquired chemo-resistance in
gastric cancer. Mol Cancer. 19:432020. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Zhao J, Shen J, Mao L, Yang T, Liu J and
Hongbin S: Cancer associated fibroblast secreted miR-432-5p targets
CHAC1 to inhibit ferroptosis and promote acquired chemoresistance
in prostate cancer. Oncogene. 43:2104–2114. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Zong WX, Rabinowitz JD and White E:
Mitochondria and cancer. Mol Cell. 61:667–676. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Li X, Zhong Y, Lu J, Axcrona K, Eide L,
Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, et al: MtDNA
depleted PC3 cells exhibit Warburg effect and cancer stem cell
features. Oncotarget. 7:40297–40313. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Gonzalez-Sanchez E, Marin JJ and Perez MJ:
The expression of genes involved in hepatocellular carcinoma
chemoresistance is affected by mitochondrial genome depletion. Mol
Pharm. 11:1856–1868. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Lee W, Choi HI, Kim MJ and Park SY:
Depletion of mitochondrial DNA up-regulates the expression of MDR1
gene via an increase in mRNA stability. Exp Mol Med. 40:109–117.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Guerra F, Arbini AA and Moro L:
Mitochondria and cancer chemoresistance. Biochim Biophys Acta
Bioenerg. 1858:686–699. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Yang H, Villani RM, Wang H, Simpson MJ,
Roberts MS, Tang M and Liang X: The role of cellular reactive
oxygen species in cancer chemotherapy. J Exp Clin Cancer Res.
37:2662018. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Orrenius S, Gogvadze V and Zhivotovsky B:
Calcium and mitochondria in the regulation of cell death. Biochem
Biophys Res Commun. 460:72–81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Seong JB, Kim B, Kim S, Kim MH, Park YH,
Lee Y, Lee HJ, Hong CW and Lee DS: Macrophage peroxiredoxin 5
deficiency promotes lung cancer progression via ROS-dependent
M2-like polarization. Free Radic Biol Med. 176:322–334. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Jeong H, Kim S, Hong BJ, Lee CJ, Kim YE,
Bok S, Oh JM, Gwak SH, Yoo MY, Lee MS, et al: Tumor-associated
macrophages enhance tumor hypoxia and aerobic glycolysis. Cancer
Res. 79:795–806. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang
Z, Zhang J, Wang Y, Yan W, Fu Z and You Y: MicroRNA-125b-2 confers
human glioblastoma stem cells resistance to temozolomide through
the mitochondrial pathway of apoptosis. Int J Oncol. 40:119–129.
2012.
|
|
202
|
Kuo CL, Ponneri Babuharisankar A, Lin YC,
Lien HW, Lo YK, Chou HY, Tangeda V, Cheng LC, Cheng AN and Lee AY:
Mitochondrial oxidative stress in the tumor microenvironment and
cancer immunoescape: Foe or friend? J Biomed Sci. 29:742022.
View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Liu JS, Yeh CA, Huang IC, Huang GY, Chiu
CH, Mahalakshmi B, Wen SY, Huang CY and Kuo WW: Signal transducer
and activator of transcription 3 mediates apoptosis inhibition
through reducing mitochondrial ROS and activating Bcl-2 in
gemcitabine-resistant lung cancer A549 cells. J Cell Physiol.
236:3896–3905. 2021. View Article : Google Scholar
|
|
204
|
Katopodi V, Marino A, Pateraki N,
Verheyden Y, Cinque S, Jimenez EL, Adnane S, Demesmaeker E,
Scomparin A, Derua R, et al: The long non-coding RNA ROSALIND
protects the mitochondrial translational machinery from oxidative
damage. Cell Death Differ. 32:397–415. 2025. View Article : Google Scholar
|
|
205
|
Fernández-Tussy P, Rodríguez-Agudo R,
Fernández-Ramos D, Barbier-Torres L, Zubiete-Franco I, Davalillo
SL, Herraez E, Goikoetxea-Usandizaga N, Lachiondo-Ortega S, Simón
J, et al: Anti-miR-518d-5p overcomes liver tumor cell death
resistance through mitochondrial activity. Cell Death Dis.
12:5552021. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Fan S, Tian T, Chen W, Lv X, Lei X, Zhang
H, Sun S, Cai L, Pan G, He L, et al: Mitochondrial miRNA determines
chemoresistance by reprogramming metabolism and regulating
mitochondrial transcription. Cancer Res. 79:1069–1084. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Orre C, Dieu X, Guillon J, Gueguen N,
Ahmadpour ST, Dumas JF, Khiati S, Reynier P, Lenaers G, Coqueret O,
et al: The long non-coding RNA SAMMSON is a regulator of
chemosensitivity and metabolic orientation in MCF-7
doxorubicin-resistant breast cancer cells. Biology (Basel).
10:11562021.PubMed/NCBI
|
|
208
|
Hillman Y, Mardamshina M, Pasmanik-Chor M,
Ziporen L, Geiger T, Shomron N and Fishelson Z: MicroRNAs affect
complement regulator expression and mitochondrial activity to
modulate cell resistance to complement-dependent cytotoxicity.
Cancer Immunol Res. 7:1970–1983. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Luan T, Fu S, Huang L, Zuo Y, Ding M, Li
N, Chen J, Wang H and Wang J: MicroRNA-98 promotes drug resistance
and regulates mitochondrial dynamics by targeting LASS2 in bladder
cancer cells. Exp Cell Res. 373:188–197. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Chen W, Wang P, Lu Y, Jin T, Lei X, Liu M,
Zhuang P, Liao J, Lin Z, Li B, et al: Decreased expression of
mitochondrial miR-5787 contributes to chemoresistance by
reprogramming glucose metabolism and inhibiting MT-CO3 translation.
Theranostics. 9:5739–5754. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Benassi B, Marani M, Loda M and Blandino
G: USP2a alters chemotherapeutic response by modulating redox. Cell
Death Dis. 4:e8122013. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Zheng ZG, Xu H, Suo SS, Xu XL, Ni MW, Gu
LH, Chen W, Wang LY, Zhao Y, Tian B and Hua YJ: The essential role
of H19 contributing to cisplatin resistance by regulating
glutathione metabolism in high-grade serous ovarian cancer. Sci
Rep. 6:260932016. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Ueda S, Takanashi M, Sudo K, Kanekura K
and Kuroda M: miR-27a ameliorates chemoresistance of breast cancer
cells by disruption of reactive oxygen species homeostasis and
impairment of autophagy. Lab Invest. 100:863–873. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Yang Q, Li K, Huang X, Zhao C, Mei Y, Li
X, Jiao L and Yang H: lncRNA SLC7A11-AS1 promotes chemoresistance
by blocking SCFβ−TRCP-mediated degradation of NRF2 in
pancreatic cancer. Mol Ther Nucleic Acids. 19:974–985. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Kaur R, Kanthaje S, Taneja S, Dhiman RK
and Chakraborti A: miR-23b-3p modulating cytoprotective autophagy
and glutamine addiction in sorafenib resistant HepG2, a
hepatocellular carcinoma cell line. Genes (Basel). 13:13752022.
View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Liu X, Chen L and Wang T: Overcoming
cisplatin resistance of human lung cancer by sinomenine through
targeting the miR-200a-3p-GLS axis. J Chemother. 35:357–366. 2023.
View Article : Google Scholar
|
|
217
|
Zhou X, Wei P, Wang X, Zhang J and Shi Y:
miR-141-3p promotes the cisplatin sensitivity of osteosarcoma cell
through targeting the glutaminase [GLS]-mediated glutamine
metabolism. Curr Mol Med. 23:177–184. 2023. View Article : Google Scholar
|
|
218
|
Chang X, Zhu W, Zhang H and Lian S:
Sensitization of melanoma cells to temozolomide by overexpression
of microRNA 203 through direct targeting of glutaminase-mediated
glutamine metabolism. Clin Exp Dermatol. 42:614–621. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Chen Z, Wang Q, Huang L, Xu G and Hu J:
LncRNA PVT1 confers cisplatin resistance of esophageal cancer cells
through Modulating the miR-181a-5p-Glutaminase (GLS) axis. Nutr
Cancer. 75:1646–1657. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Lin W, Wu WC, Liang Z, Zhang JH and Fang
SP: LncRNA FEZF1-AS1 facilitates cisplatin resistance in non-small
cell lung cancer through modulating the miR-32-5p-glutaminase axis.
Am J Cancer Res. 14:3153–3170. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
De Los Santos-Jiménez J, Campos-Sandoval
JA, Alonso FJ, Márquez J and Matés JM: GLS and GLS2 glutaminase
isoenzymes in the antioxidant system of cancer cells. Antioxidants
(Basel). 13:7452024. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Li Y, Yuan S, Zhou Y, Zhou J, Zhang X,
Zhang P, Xiao W, Zhang Y, Deng J and Lou S: Long non-coding RNA
PXN-AS1 promotes glutamine synthetase-mediated chronic myeloid
leukemia BCR::ABL1-independent resistance to Imatinib via cell
cycle signaling pathway. Cancer Cell Int. 24:1862024. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Montani F and Bianchi F: Circulating
cancer biomarkers: The macro-revolution of the micro-RNA.
EBioMedicine. 5:4–6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Sarfi M, Abbastabar M and Khalili E: Long
noncoding RNAs biomarker-based cancer assessment. J Cell Physiol.
234:16971–16986. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Liu R, Zeng Y, Zhou CF, Wang Y, Li X, Liu
ZQ, Chen XP, Zhang W and Zhou HH: Long noncoding RNA expression
signature to predict platinum-based chemotherapeutic sensitivity of
ovarian cancer patients. Sci Rep. 7:182017. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Wang Q, Zheng C, Hou H, Bao X, Tai H,
Huang X, Li Z, Li Z, Wang Q, Pan Q, et al: Interplay of
sphingolipid metabolism in predicting prognosis of GBM patients:
Towards precision immunotherapy. J Cancer. 15:275–292. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Bacci M, Giannoni E, Fearns A, Ribas R,
Gao Q, Taddei ML, Pintus G, Dowsett M, Isacke CM, Martin LA, et al:
miR-155 drives metabolic reprogramming of ER+ breast cancer cells
following long-term estrogen deprivation and predicts clinical
response to aromatase inhibitors. Cancer Res. 76:1615–1626. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Lei H, Xiang T, Zhu H and Hu X: A novel
cholesterol metabolism-related lncRNA signature predicts the
prognosis of patients with hepatocellular carcinoma and their
response to immunotherapy. Front Biosci (Landmark Ed). 29:1292024.
View Article : Google Scholar : PubMed/NCBI
|
|
229
|
He X, Xu Z, Ren R, Wan P, Zhang Y, Wang L
and Han Y: A novel sphingolipid metabolism-related long noncoding
RNA signature predicts the prognosis, immune landscape and
therapeutic response in pancreatic adenocarcinoma. Heliyon.
10:e236592023. View Article : Google Scholar
|
|
230
|
Wang X, Yang X, Zhang Y, Guo A, Luo S,
Xiao M, Xue L, Zhang G and Wang H: Fatty acid metabolism-related
lncRNAs are potential biomarkers for predicting prognoses and
immune responses in patients with skin cutaneous melanoma. Clin
Cosmet Investig Dermatol. 16:3595–3614. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Bayarmaa B, Wu Z, Peng J, Wang Y, Xu S,
Yan T, Yin W, Lu J and Zhou L: Association of LncRNA MEG3
polymorphisms with efficacy of neoadjuvant chemotherapy in breast
cancer. BMC Cancer. 19:8772019. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Xu W, Hua Y, Deng F, Wang D, Wu Y, Zhang W
and Tang J: MiR-145 in cancer therapy resistance and sensitivity: A
comprehensive review. Cancer Sci. 111:3122–3131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Hedayat S, Cascione L, Cunningham D,
Schirripa M, Lampis A, Hahne JC, Tunariu N, Hong SP, Marchetti S,
Khan K, et al: Circulating microRNA analysis in a prospective
co-clinical trial identifies MIR652-3p as a response biomarker and
driver of regorafenib resistance mechanisms in colorectal cancer.
Clin Cancer Res. 30:2140–2159. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Gonçalves AC, Richiardone E, Jorge J,
Polónia B, Xavier CPR, Salaroglio IC, Riganti C, Vasconcelos MH,
Corbet C and Sarmento-Ribeiro AB: Impact of cancer metabolism on
therapy resistance-clinical implications. Drug Resist Updat.
59:1007972021. View Article : Google Scholar
|
|
235
|
Abdel-Wahab AF, Mahmoud W and Al-Harizy
RM: Targeting glucose metabolism to suppress cancer progression:
Prospective of anti-glycolytic cancer therapy. Pharmacol Res.
150:1045112019. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Sun Z, Zhang Q, Yuan W, Li X, Chen C, Guo
Y, Shao B, Dang Q, Zhou Q, Wang Q, et al: MiR-103a-3p promotes
tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis. J
Exp Clin Cancer Res. 39:2502020. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Fujiwara N, Inoue J, Kawano T, Tanimoto K,
Kozaki K and Inazawa J: miR-634 activates the mitochondrial
apoptosis pathway and enhances chemotherapy-induced cytotoxicity.
Cancer Res. 75:3890–3901. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Medina PP, Nolde M and Slack FJ: OncomiR
addiction in an in vivo model of microRNA-21-induced pre-B-cell
lymphoma. Nature. 467:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Chen B, Dragomir MP, Yang C, Li Q, Horst D
and Calin GA: Targeting non-coding RNAs to overcome cancer therapy
resistance. Signal Transduct Target Ther. 7:1212022. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Kara G, Calin GA and Ozpolat B: RNAi-based
therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv
Rev. 182:1141132022. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Yadav DN, Ali MS, Thanekar AM, Pogu SV and
Rengan AK: Recent advancements in the design of nanodelivery
systems of siRNA for cancer therapy. Mol Pharm. 19:4506–4526. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Garbo S, Maione R, Tripodi M and
Battistelli C: Next RNA therapeutics: The mine of non-coding. Int J
Mol Sci. 23:74712022. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Lin F, Wen D, Wang X and Mahato RI: Dual
responsive micelles capable of modulating miRNA-34a to combat
taxane resistance in prostate cancer. Biomaterials. 192:95–108.
2019. View Article : Google Scholar
|
|
244
|
Xin X, Kumar V, Lin F, Kumar V, Bhattarai
R, Bhatt VR, Tan C and Mahato RI: Redox-responsive nanoplatform for
codelivery of miR-519c and gemcitabine for pancreatic cancer
therapy. Sci Adv. 6:eabd67642020. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Guo W, Wu Z, Chen J, Guo S, You W, Wang S,
Ma J, Wang H, Wang X, Wang H, et al: Nanoparticle delivery of
miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by
promoting ferroptosis. J Immunother Cancer. 10:e0043812022.
View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Xu F, Ye ML, Zhang YP, Li WJ, Li MT, Wang
HZ, Qiu X, Xu Y, Yin JW, Hu Q, et al: MicroRNA-375-3p enhances
chemosensitivity to 5-fluorouracil by targeting thymidylate
synthase in colorectal cancer. Cancer Sci. 111:1528–1541. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Lo YL, Wang CS, Chen YC, Wang TY, Chang
YH, Chen CJ and Yang CP: Mitochondrion-directed nanoparticles
loaded with a natural compound and a microRNA for promoting cancer
cell death via the modulation of tumor metabolism and mitochondrial
dynamics. Pharmaceutics. 12:7562020. View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Yi WR, Tu MJ, Yu AX, Lin J and Yu AM:
Bioengineered miR-34a modulates mitochondrial inner membrane
protein 17 like 2 (MPV17L2) expression toward the control of cancer
cell mitochondrial functions. Bioengineered. 13:12489–12503. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Yi W, Tu MJ, Liu Z, Zhang C, Batra N, Yu
AX and Yu AM: Bioengineered miR-328-3p modulates GLUT1-mediated
glucose uptake and metabolism to exert synergistic
antiproliferative effects with chemotherapeutics. Acta Pharm Sin B.
10:159–170. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Vahabi M, Comandatore A, Franczak MA,
Smolenski RT, Peters GJ, Morelli L and Giovannetti E: Role of
exosomes in transferring chemoresistance through modulation of
cancer glycolytic cell metabolism. Cytokine Growth Factor Rev.
73:163–172. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
251
|
Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si
K, Sun B, Chen B and Xiao Z: Engineered exosomes for targeted
co-delivery of miR-21 inhibitor and chemotherapeutics to reverse
drug resistance in colon cancer. J Nanobiotechnology. 18:102020.
View Article : Google Scholar : PubMed/NCBI
|
|
252
|
El Moukhtari SH, Garbayo E, Amundarain A,
Pascual-Gil S, Carrasco-León A, Prosper F, Agirre X and
Blanco-Prieto MJ: Lipid nanoparticles for siRNA delivery in cancer
treatment. J Control Release. 361:130–146. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Tassone P, Di Martino MT, Arbitrio M,
Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci
B, Salvino A, et al: Safety and activity of the first-in-class
locked nucleic acid (LNA) miR-221 selective inhibitor in refractory
advanced cancer patients: a first-in-human, phase 1, open-label,
dose-escalation study. J Hematol Oncol. 16:682023. View Article : Google Scholar : PubMed/NCBI
|
|
254
|
Yang S, Wang X, Zhou X, Hou L, Wu J, Zhang
W, Li H, Gao C and Sun C: ncRNA-mediated ceRNA regulatory network:
Transcriptomic insights into breast cancer progression and
treatment strategies. Biomed Pharmacother. 162:1146982023.
View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Yu J, Qi J, Sun X, Wang W, Wei G, Wu Y,
Gao Q and Zheng J: MicroRNA-181a promotes cell proliferation and
inhibits apoptosis in gastric cancer by targeting RASSF1A. Oncol
Rep. 40:1959–1970. 2018.PubMed/NCBI
|
|
256
|
Zhang LX, Gao J, Long X, Zhang PF, Yang X,
Zhu SQ, Pei X, Qiu BQ, Chen SW, Lu F, et al: The circular RNA
circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung
adenocarcinomas and squamous cell carcinomas via the
miR-181a-5p/CARM1 axis. Mol Cancer. 21:1102022. View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Lehuédé C, Dupuy F, Rabinovitch R, Jones
RG and Siegel PM: Metabolic plasticity as a determinant of tumor
growth and metastasis. Cancer Res. 76:5201–5208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
258
|
Hu X, Li J, Fu M, Zhao X and Wang W: The
JAK/STAT signaling pathway: From bench to clinic. Signal Transduct
Target Ther. 6:4022021. View Article : Google Scholar : PubMed/NCBI
|
|
259
|
Xiao C, Zhang W, Hua M, Chen H, Yang B,
Wang Y and Yang Q: RNF7 inhibits apoptosis and sunitinib
sensitivity and promotes glycolysis in renal cell carcinoma via the
SOCS1/JAK/STAT3 feedback loop. Cell Mol Biol Lett. 27:362022.
View Article : Google Scholar : PubMed/NCBI
|
|
260
|
Wang T, Fahrmann JF, Lee H, Li YJ,
Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan Y, et al:
JAK/STAT3-regulated fatty acid β-oxidation is critical for breast
cancer stem cell self-renewal and chemoresistance. Cell Metab.
27:136–150.e5. 2018. View Article : Google Scholar
|
|
261
|
Yin YZ, Zheng WH, Zhang X, Chen YH and Tuo
YH: LINC00346 promotes hepatocellular carcinoma progression via
activating the JAK-STAT3 signaling pathway. J Cell Biochem.
121:735–742. 2020. View Article : Google Scholar
|
|
262
|
Hu H, Zhang Q, Chen W, Wu T, Liu S, Li X,
Luo B, Zhang T, Yan G, Lu H and Lu Z: MicroRNA-301a promotes
pancreatic cancer invasion and metastasis through the JAK/STAT3
signaling pathway by targeting SOCS5. Carcinogenesis. 41:502–514.
2020. View Article : Google Scholar
|
|
263
|
Sulli G, Lam MTY and Panda S: Interplay
between circadian clock and cancer: New frontiers for cancer
treatment. Trends Cancer. 5:475–494. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
264
|
Varadharaj V, Petersen W, Batra SK and
Ponnusamy MP: Sugar symphony: Glycosylation in cancer metabolism
and stemness. Trends Cell Biol. Oct 26–2024.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
265
|
Yang Y, Yang T, Zhao Z, Zhang H, Yuan P,
Wang G, Zhao Z, An J, Lyu Z, Xing J and Li J: Down-regulation of
BMAL1 by MiR-494-3p promotes hepatocellular carcinoma growth and
metastasis by increasing GPAM-mediated lipid biosynthesis. Int J
Biol Sci. 18:6129–6144. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
266
|
Zheng LT, Chen SR, Zhou LY, Huang QY, Chen
JM, Chen WH, Lin S and Shi QY: Latest advances in the study of
non-coding RNA-mediated circadian rhythm disorders causing
endometrial cancer. Front Oncol. 13:12775432023. View Article : Google Scholar : PubMed/NCBI
|
|
267
|
Alsayed RKME, Sheikhan KSAM, Alam MA,
Buddenkotte J, Steinhoff M, Uddin S and Ahmad A: Epigenetic
programing of cancer stemness by transcription factors-non-coding
RNAs interactions. Semin Cancer Biol. 92:74–83. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
268
|
Jiang W, Zhao S, Shen J, Guo L, Sun Y, Zhu
Y, Ma Z, Zhang X, Hu Y, Xiao W, et al: The MiR-135b-BMAL1-YY1 loop
disturbs pancreatic clockwork to promote tumourigenesis and
chemoresistance. Cell Death Dis. 9:1492018. View Article : Google Scholar : PubMed/NCBI
|
|
269
|
Flores-Huerta N, Silva-Cázares MB,
Arriaga-Pizano LA, Prieto-Chávez JL and López-Camarillo C: LncRNAs
and microRNAs as essential regulators of stemness in breast cancer
stem cells. Biomolecules. 11:3802021. View Article : Google Scholar : PubMed/NCBI
|
|
270
|
Jiao X, Qian X, Wu L, Li B, Wang Y, Kong X
and Xiong L: microRNA: The impact on cancer stemness and
therapeutic resistance. Cells. 9:82019. View Article : Google Scholar : PubMed/NCBI
|
|
271
|
Hong DS, Kang YK, Borad M, Sachdev J,
Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, et al: Phase 1
study of MRX34, a liposomal miR-34a mimic, in patients with
advanced solid tumours. Br J Cancer. 122:1630–1637. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
272
|
Patil S, Gao YG, Lin X, Li Y, Dang K, Tian
Y, Zhang WJ, Jiang SF, Qadir A and Qian AR: The development of
functional non-viral vectors for gene delivery. Int J Mol Sci.
20:54912019. View Article : Google Scholar : PubMed/NCBI
|
|
273
|
Oggu GS, Sasikumar S, Reddy N, Ella KKR,
Rao CM and Bokara KK: Gene delivery approaches for mesenchymal stem
cell therapy: Strategies to increase efficiency and specificity.
Stem Cell Rev Rep. 13:725–740. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
274
|
Yahya EB and Alqadhi AM: Recent trends in
cancer therapy: A review on the current state of gene delivery.
Life Sci. 269:1190872021. View Article : Google Scholar : PubMed/NCBI
|
|
275
|
Aleksakhina SN, Kashyap A and Imyanitov
EN: Mechanisms of acquired tumor drug resistance. Biochim Biophys
Acta Rev Cancer. 1872:1883102019. View Article : Google Scholar : PubMed/NCBI
|
